S&P 500 and Nasdaq 100 Testing Prior 2022 Highs Since late-February (2/25/25 Compass) we expected an 8-10% pullback to provide a buying opportunity. But that all changed in last week's Compass (4/1/25), when we downgraded our outlook to bearish/cautious, citing several concerning developments (SPX and QQQ failure at 200-day MAs, bear flag breakdowns across major indexes targeting 5100-5200 on SPX, high yield spreads widening above 355bps, major tops on market leaders NVDA and META, semiconducto...
Two Directors at Abbvie Inc sold/sold after exercising options/gave away 61,288 shares at between 0.000USD and 210.081USD. The significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by al...
Near-Term Downside Likely Following False Breakouts Our long-term outlook remains bullish as long as the S&P 500 remains above 5770-5850 and 5600-5670 (worst case), and we are buyers at these levels. With that said, we see potential for near-term downside as the S&P 500, Nasdaq 100 (QQQ), and FANG+ (FNGS) (1) could not decisively break out to new highs, (2) display bearish false breakouts, (3) have fallen back into their 2+ month trading ranges, (4) are violating their 1+ month uptrends, and (5...
Moody's Ratings (Moody's) assigned an A3 rating to the new senior unsecured notes issuance of AbbVie Inc. ("AbbVie"). There are no changes to AbbVie's existing ratings including the A3 senior unsecured rating and the Prime-2 short-term rating, or the positive outlook. Proceeds of the offering will...
Moody's Ratings (Moody's) affirmed the ratings of AbbVie Inc. ("AbbVie") including the A3 senior unsecured notes, A3 issuer rating and the Prime-2 senior unsecured commercial paper rating. At the same time, we revised AbbVie's outlook to positive from stable. The change in AbbVie's outlook to posi...
Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...
Moody's Investors Service ("Moody's") affirmed the ratings of AbbVie Inc. ("AbbVie") including the A3 senior unsecured notes, issuer rating and the Prime-2 senior unsecured commercial paper ratings. The outlook is maintained at stable. These actions follow the announcement that AbbVie will acquire C...
Moody's Investors Service commented that AbbVie Inc.'s announcement that it will acquire ImmunoGen, Inc. for approximately $10.1 billon will enhance its oncology franchise by adding the approved drug Elahere to AbbVie's portfolio. The acquisition also brings oncology pipeline opportunities including...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.